loading…
As many as 82% or 2,214 people with hemophilia in Indonesia have type A hemophilia and the rest are hemophilia B. Of the number of people with hemophilia A, 58% of them are children aged 0-18 years.
People with hemophilia A lack blood clotting factor VIII (factor VIII), where the blood cannot clot normally so that the patient will experience prolonged and even uncontrollable bleeding episodes due to a light impact or because of bleeding that occurs spontaneously (without impact).
Also Read: Epigallo content in Green Tea Can Reduce the Dangers of COVID-19
People with hemophilia also have serious health risks in the form of joint swelling, disability and even life-threatening. Especially for children, this condition often restricts them from being able to carry out normal activities.
Health facilities that are still centralized in big cities and limited resources coupled with the spread of population in various islands in Indonesia pose several challenges for people to get access to hemophilia management services.
Chairman of the Indonesian Hemophilia Society Association Prof. dr. Djajadiman Gatot, Sp.A (K) said, there is still a lot of public ignorance about the symptoms and treatment of hemophilia. In fact, the incidence of hemophilia requires special and immediate handling so as not to pose serious risks in the long term.
Hemophilia treatment is currently supported by the government through the National Health Insurance or BPJS, so that people with hemophilia in Indonesia can get the clotting factor treatment they need. “However, there are still some obstacles related to the amount of medicine and the inadequate dosage so that many patients experience joint damage, heavy bleeding such as bleeding from the brain and internal organs at risk of death,” explained Prof. Djajadiman in a Virtual Media Briefing, some time ago.
– .
